Clinical Trial Update: Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of nimotuzumab with gemcitabine and carboplatin for unresectable Stage III squamous cell lung carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Cancer | Phase 2 | Status: WITHDRAWN